CLX001 / ValiRx - LARVOL DELTA

ValiRx signs IP license agreement with Kings College London to progress triple negative breast cancer treatment (ValiRx Press Release) - "ValiRx PLC has announced the formation of a new subsidiary company, Cytolytix Limited, which has signed an IP license agreement with Kings College London to progress the preclinical development of its triple negative breast cancer treatment, CLX001....CLX001 is a peptide in a nanoparticle formulation, developed for the treatment of triple negative breast cancer, with potential for expansion into ovarian cancer and other solid tumour cancers....As the major shareholder in Cytolytix, ValiRx will lead the development of CLX001 with oversight provided by the Cytolytix board, which comprises representatives from ValiRx, Kings College London, and Martin Ulmschneider, an academic inventor of CLX001. Under the IP license agreement, ValiRx will provide the necessary funding to Cytolytix for further preclinical development of the technology."

Licensing / partnership • Breast Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer